Study S000666

Emulation of Effects of Injectable Semaglutide on Cardiovascular Outcomes in Individuals With Type 2 Diabetes: SUSTAIN6 Trial

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan: Study Protocol for Three-Stage Project (PDF)Study Protocol and Statistical Analysis Plan: Study Protocol for Two-Stage Project (PDF)Study Protocol and Statistical Analysis Plan: Amendment to Study Protocol for Two-Stage Project (PDF)

Registration

Registration: NCT06659744
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 158310
Start: 2024-10-24
Primary completion: 2025-03-06
Lead sponsor: Brigham and Women's Hospital
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:New use of semaglutide injection; DRUG:New initiation of sitagliptin
Results posted: FALSE

Registered primary outcomes

Major adverse cardiac event (MACE), including myocardial infarction, stroke, and all cause death [Through study completion (1 day after cohort entry date until the first of outcome or censoring)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007550	Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice. Krüger N, Nature medicine	2026	Randomized trial	PMID 41207920 DOI	cites ClinicalTrials.gov:NCT06659744; registry reference DERIVED:41207920